Separate science from politics: save the UK’s science sector
LifeArc's Chief Scientific Officer calls for UK science to continue to be a contributor to the Horizon Europe programme.
🎬 That's a wrap for this year's @ELRIG_UK #DrugDiscovery conference!
Thanks to everyone who came by our exhibition… https://t.co/VpNz7YqS4l
Promising new antibody treatment for osteoporosis and multiple sclerosis
The new antibody offers hope of an effective new treatment option for millions of people.
Covid-19 hub shortlisted for Scottish award
Unique translational research hub for Covid-19 and other viruses was a finalist in the Scottish Knowledge Exchange Awards.Â
LifeArc bolsters scientific leadership by appointing new Chief Scientific Officer
Welcome to Dr Dave Powell, who has joined LifeArc as our first Chief Scientific Officer (CSO).  Dave is an experienced scientist and leader, with…
New approach provides potential vaccine and treatment for Alzheimer’s
An antibody-based treatment and protein-based vaccine reduced Alzheimer’s symptoms in mouse models of the disease.
Advanced diagnosis for patients with rare conditions
This week, results from the 100,000 Genomes Project showed that whole genome sequencing improves the diagnosis of…
Kickstart drug repurposing: smashing the roadblocks on the route to patients
How LifeArc aims to support charities, researchers and funders exploring new uses for existing medicines
LifeArc appoints Dr Ian Campbell as Chief Business Officer
Former Innovate UK Executive Chair joins charity to drive new collaborations and partnerships to benefit patient health.
LifeArc boosts investment in Cambridge University spin-out PolyProx Therapeutics to advance new class of cancer medicines
The investment will help advance studies to validate polyproxin® molecules as potential drug candidates across a range of cancers.